Jilin Jian Yisheng Pharmaceutical Co Ltd
SZSE:002566
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (27.9), the stock would be worth ¥4.34 (44% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 49.5 | ¥7.7 |
0%
|
| 3-Year Average | 27.9 | ¥4.34 |
-44%
|
| 5-Year Average | 25.4 | ¥3.96 |
-49%
|
| Industry Average | 23.4 | ¥3.65 |
-53%
|
| Country Average | 28.9 | ¥4.49 |
-42%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Jilin Jian Yisheng Pharmaceutical Co Ltd
SZSE:002566
|
2.5B CNY | 49.5 | 63.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 29.2 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 21.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 22 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 15.6 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 11.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.8 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 10.1 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 8.9 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Jilin Jian Yisheng Pharmaceutical Co Ltd
Glance View
Jilin Jian Yisheng Pharmaceutical Co., Ltd. engages in the research and development, production, and distribution of Chinese patent medicines. The company is headquartered in Tonghua, Jilin and currently employs 1,712 full-time employees. The company went IPO on 2011-03-18. The Company’s main products consist of Shengmai injections, Zhenyuan capsules, Xinyue capsules, Qingkailing injections and Guifu Dihuang capsules, among others. The firm's products are applied in the treatment for heart cerebrovascular diseases and detoxification. The firm also provides health care products and cosmetics. The firm distributes its products within China market.
